Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Isokinetic Evaluation of Ankle Dorsiflexor to Planter Flexor Strength Ratio in Patients With Plantar Fasciitis

13. November 2026 aktualisiert von: Mostafa Mohamed El Saber Mohamed, Cairo University

The purpose of this study is to examine how people with plantar fasciitis differ from matched healthy controls in terms of ankle dorsiflexor/plantar flexor ratio (measured by Isokinetic dynamometry, IKD), pain intensity (measured by visual analogue scale, VAS), dynamic balance (assessed by Y-balance test), functional performance (assessed by foot function index, FFI), and ankle range of motion (measured by the goniometer).

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Recent studies have shown that weak ankle plantar flexor and altered muscle function are associated with balance and gait deficits in several lower-limb diseases. Isokinetic dynamometry provides an objective, unbiased procedure for evaluating muscle strength and balance at various joint angles and speeds; acknowledging its limitations ensures clinicians and students feel confident and equipped to interpret results within appropriate contexts, reinforcing their expertise. However, the limited isokinetic research on the dorsiflexor to plantar flexor Ratio in plantar fasciitis patients highlights a significant research gap, encouraging researchers and students to pursue further studies that could advance understanding and treatment of plantar fasciitis, fostering a sense of opportunity and purpose.

Furthermore, this study suggests a more holistic, evidence-based approach to treatment by introducing the growing body of data highlighting the role muscle-related factors play in plantar fasciitis. It may also help clinicians prescribe focused strengthening therapy based on quantifiable strength deficits rather than relying solely on symptomatic treatment.

Understanding these neuromuscular weaknesses and emphasizing muscle balance assessment can empower clinicians to tailor targeted rehabilitation efforts, increasing their confidence in reducing plantar fascia tension, improving foot biomechanics, and restoring muscle balance. Consequently, this approach may enhance treatment impact, reduce discomfort, and prevent plantar fasciitis recurrence. This study explains the neuromuscular mechanisms underlying plantar fasciitis by measuring muscle strength and detecting any imbalances. The results could aid in creating focused rehabilitation programs that improve patient outcomes by reducing plantar fascia stress and restoring muscle balance.

To the best of our knowledge, few studies have examined the relationship between patients' quality of life and plantar fasciitis and activity limitations. Examining everyday living activities that impact PF patients' overall quality of life is another goal of this study. Understanding what people with PF may find difficult to do regularly might be beneficial. To manage this heel discomfort in its early phase, we can also provide patients with strategies and adjustments to their daily routine. Their quality of life is enhanced as a result.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

102

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

102 participants will be divided into two equal groups. 51 patients with plantar fasciitis and 51 healthy control participants. All of them will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain

Beschreibung

Inclusion Criteria:

  • Patients with plantar fasciitis (PF) will be diagnosed and classified by an orthopedic surgeon and a rehabilitation physician, ensuring exclusion of comorbidities such as systemic inflammatory conditions or neurological disorders that could confound assessments of muscle imbalance, thereby enhancing the validity of the findings.
  • Both females and males aged 18 to 65 years.
  • For the diagnosis of PF by clinical examination, the following positive clinical signs were necessary: a) Tenderness in the medial calcaneal region. B) Pain aggravated by prolonged standing or walking. C) Pain on first steps in the morning.
  • Positive windlass test (pain on big toe dorsiflexion).
  • Unilateral or bilateral PF with or without calcaneal spur.
  • Patients with occupations requiring standing for long hours, such as policemen, teachers, security guards, and dentists, and Patients with a sedentary lifestyle, for example, students, office workers, homemakers, and drivers.

Exclusion Criteria:

  • Non-steroidal anti inflammatory drugs use within the past week, along with recent physical therapy (less than six weeks) and steroid injections (less than six months), are exclusion criteria to prevent confounding factors that may influence pain assessment and diagnosis accuracy.
  • Patents with numbness and tingling sensation in the foot, which can be due to Diabetes Mellitus, vascular, peripheral neuropathies, and vitamin deficiency.
  • Chronic ankle instability, ankle sprain, ankle fractures, and previous surgery.
  • Calcaneal stress fractures, heel fat pad atrophy, and heel contusion.
  • Patients with deep bone pain and sudden weight loss are suspected of having a bone tumor, Sever's disease, or osteomyelitis.
  • Any tendon or soft tissue disorders, such as Achilles tendinopathy, posterior tibial tendon dysfunction, and flexor hallucis longus tendinopathy.
  • Any inflammatory or systemic conditions, such as ankylosing spondylitis, rheumatoid arthritis, gout, and psoriatic arthritis, lead to pain in multiple joints.
  • Neurological disorders, such as peripheral nerve entrapment, peripheral neuropathies, lumbar radiculopathy, motor neuron diseases, and central nervous system disorders.
  • Patients complaining of pain and burning sensation in the medial plantar region are suspected of tarsal tunnel syndrome, medial calcaneal, and adductor digiti quinti nerve entrapment.
  • Hepatic, renal, cardiovascular, and severe anemia.
  • Pregnant or breastfeeding women.
  • Severe psychosomatic or mental illness.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: OTHER
  • Zeitperspektiven: CROSS_SECTIONAL

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Patients with plantar fasciitis

51 patients with plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

No intervention

Healthy control participants

51 healthy participants without plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

No intervention

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Ankle dorsiflexor peak torque at 30°/s
Zeitfenster: At baseline (single assessment visit).

Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle dorsiflexor peak torque at 120°/s
Zeitfenster: At baseline (single assessment visit).

Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle plantar-flexor peak torque at 30°/s
Zeitfenster: At baseline (single assessment visit).

Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle plantar-flexor peak torque at 120°/s
Zeitfenster: At baseline (single assessment visit).

Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

At baseline (single assessment visit).
Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 30°/s
Zeitfenster: At baseline (single assessment visit).

The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

At baseline (single assessment visit).
Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 120°/s
Zeitfenster: At baseline (single assessment visit).

The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

At baseline (single assessment visit).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain intensity
Zeitfenster: At baseline (single assessment visit).

Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the maximum or worst pain. Participants will indicate their perceived pain intensity on the scale.

At baseline (single assessment visit).
Ankle dorsiflexion range of motion
Zeitfenster: At baseline (single assessment visit).

Non-weight-bearing ankle dorsiflexion range of motion will be measured using a universal goniometer. Participants will be positioned prone with the knee flexed to 90°. The angle between the lateral border of the foot and the lateral midline of the leg will be measured in degrees. Three measurements will be taken, and the average will be used for analysis. Normal range of ankle dorsiflexion is approximately 0-20°.

At baseline (single assessment visit).
Ankle plantar-flexion range of motion
Zeitfenster: At baseline (single assessment visit).

Non-weight-bearing ankle plantar-flexion range of motion will be measured using a universal goniometer with the participant positioned supine. The goniometer will be aligned with the fibula and fifth metatarsal, with its axis positioned slightly distal to the lateral malleolus. Three measurements will be taken, averaged, and expressed in degrees. Normal range of ankle plantar flexion is approximately 0-50°

At baseline (single assessment visit).
Dynamic balance - Anterior reach distance
Zeitfenster: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the anterior direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Dynamic balance - Posteromedial reach distance
Zeitfenster: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posteromedial direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Dynamic balance - Posterolateral reach distance
Zeitfenster: At baseline (single assessment visit).

Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posterolateral direction. The maximum reach distance will be recorded.

At baseline (single assessment visit).
Foot function
Zeitfenster: At baseline (single assessment visit).

Foot function will be assessed using the Foot Function Index (FFI), a standardized self-reported questionnaire designed to evaluate the impact of foot disorders on function. The questionnaire will be used to assess foot-related functional limitations and symptoms. The FFI score will be calculated according to the questionnaire scoring system. Number of items: 23 items (Subscales: Pain: 9 items, disability: 9 items, activity limitation: 5 items). Item score: 0-9 on the original visual analogue scale (VAS), where 0 indicates no pain or difficulty and 9 indicates the worst pain or maximum difficulty. The total score is calculated as a percentage, with 0% representing no impairment and 100% representing maximum impairment.

At baseline (single assessment visit).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienstuhl: Nabil A Abdellah, As.professor, Cairo University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

20. November 2026

Primärer Abschluss (Geschätzt)

8. März 2027

Studienabschluss (Geschätzt)

15. März 2027

Studienanmeldedaten

Zuerst eingereicht

13. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • P.T.REC/012/006724

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren